comparemela.com

Latest Breaking News On - Vicki kelemen - Page 1 : comparemela.com

Cardiff Oncology to Present at the William Blair Biotech Focus Conference 2022

/PRNewswire/ Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a.

Amy jobeVicki kelemenJoyce allaireCardiff oncology incLifesci communicationsCardiff oncologyWilliam blair biotech focus conferenceRegis new yorkOncology contactOperating officerSci advisorsSci communications

Cardiff Oncology to Present at the H C Wainwright Global Investment Conference

/PRNewswire/ Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a.

United statesAmy jobeVicki kelemenJoyce allaireCardiff oncology incLifesci communicationsPrnewswire cardiff oncology incGlobal investment conferenceCardiff oncologyOncology contact

Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual Meeting

Trial evaluates onvansertib in combination with abiraterone and prednisone in metastatic castration-resistant prostate cancer (mCRPC) patients showing initial.

United statesNew orleansDavid einsteinAmy jobeVicki kelemenJoyce allaireCardiff oncology incBeth israel deaconess medical centerPrnewswire cardiff oncology incErnestn morial convention centerExchange commissionAmerican association for cancer researchLifesci communicationsAmerican associationCancer researchAnnual meeting

Cardiff Oncology to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC

/PRNewswire/ Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a.

Mark erlanderAmy jobeVicki kelemenJoyce allaireCardiff oncology incMaxim groupLifesci communicationsCardiff oncologyGrowth conferenceOncology contact

Cardiff Oncology Announces Upcoming Poster Presentations at the AACR Annual Meeting

/PRNewswire/ Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a.

United statesNew orleansAmy jobeVicki kelemenJoyce allaireExchange commissionCardiff oncology incAmerican association for cancer researchLifesci communicationsErnestn morial convention centerCardiff oncologyAmerican associationCancer researchAnnual meetingConvention centerTherapeutic benefit

vimarsana © 2020. All Rights Reserved.